Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Trial of Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT07501650 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT07501650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07501650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Trial of Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
Thomas Jefferson University
Phase
Phase 1
Overall status
Recruiting
Start date
March 18, 2026
Completion date
March 31, 2028
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck small cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer